[A22-126] Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) – Addendum to Commission A22-80

Last updated 03.02.2023

Project no.:
A22-126

Commission:
Commission awarded on 06.12.2022 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Patients with unresectable or metastatic HER2-positive breast cancer who have previously received one HER2-targeted therapy

Result of dossier assessment:

After addendum now:

  • Patients < 65 years: hint of major added benefit
  • Patients ≥ 65 years: added benefit not proven
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2023-02-02 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form